Telix Pharmaceuticals Ltd — Capital/Financing Update 2021

Sep 27, 2021

Telix Pharmaceuticals Limited ACN 616 620 369 Suite 401, 55 Flemington Road North Melbourne Victoria, 3051 Australia

==> picture [146 x 81] intentionally omitted <==

$12.1M R&D Tax Refund, Overseas Finding Increased to $139M

Melbourne (Australia) – 28 September 2021 . Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has received a $12.1M R&D tax refund in relation to eligible R&D activities undertaken by the Company in the year ended 31 December 2020.

The Company is also pleased to advise that its application for an expanded overseas finding, to enable partial recovery of essential overseas R&D expenditure has been accepted by the Department of Industry, Science, Energy and Resources. On 3 August 2018 Telix received an ‘advance finding’ in relation to its proposed pre-clinical, clinical, manufacturing and regulatory-related activities.[1] The enabled the Company to claim an R&D tax rebate on eligible R&D investment, up to a gross amount of $55.2 million over five years.

The approved expansion of the advance finding will allow Telix to claim a further R&D tax rebate, or deduction on eligible R&D investment, up to a gross amount of ~$139M from the current year through to 31 December 2027.

Telix Chief Financial Officer, Mr. Doug Cubbin stated, “Given the growth in the Company’s pipeline, Telix sought an expansion to its advance overseas R&D tax finding, complementing our significant investment in Australian R&D. The Australian Federal Government’s R&D tax credit scheme is of significant value to a biotechnology company such as Telix, particularly as we transition from development to sustainable revenue stage. These funds enable the Company to invest in innovative clinical development programs and research partnerships with leading Australian institutions.”

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.

Telix’s lead investigational product, Illuccix[®] (TLX591-CDx) for prostate cancer imaging, has been accepted for filing by the U.S. FDA,[2] and is under priority evaluation by the Australian Therapeutic Goods Administration (TGA).[3] Telix is also progressing marketing authorisation applications for Illuccix[®] in the European Union[4] and Canada.[5] None of Telix’s products have received a marketing authorisation in any jurisdiction.

Telix Investor Relations

Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Corporate Communications and Investor Relations Email: kyahn.williamson@telixpharma.com

1 ASX disclosure 3/08/18.

2 ASX disclosure 24/11/20.

3 ASX disclosure 14/04/21.

4 ASX disclosure 1/05/20.

5 ASX disclosure 16/12/20.

Page 1

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the “U.S. Securities Act”), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the U.S. Securities Act or an exemption from the registration requirements of the U.S. Securities Act is available. None of the technologies or products described in this document have received a marketing authorisation in any jurisdiction. This announcement has been authorised for release by Dr Christian Behrenbruch, Managing Director and Chief Executive Officer.

Page 2